Rising BioSciences, Inc. (RBII)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rising BioSciences, Inc. (RBII) trades at $0.00. Rising BioSciences, Inc. develops and manufactures topical and oral pharmaceutical products, including medical marijuana products. Market cap: $4,991, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for RBII: RBII does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RBII against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RBII: 1/1 perspectives are bearish.
How is this calculated? →Rising BioSciences, Inc. (RBII) Healthcare & Pipeline Overview
Rising BioSciences, Inc., based in Sheridan, Wyoming, develops and manufactures topical and oral pharmaceutical products, including medical marijuana products. Operating in the healthcare sector, the company focuses on the medical pharmaceutical segment, competing with other OTC-listed and established pharmaceutical companies in a rapidly evolving market.
What Is the Investment Thesis for RBII?
Rising BioSciences, Inc. presents a speculative investment opportunity within the medical pharmaceutical sector, specifically focusing on topical and oral products, including those containing medical marijuana. With a P/E ratio of 0.21 and a profit margin of 6.4%, the company shows potential for profitability. However, the company's high beta of 4.96 indicates significant volatility. Key growth catalysts include expansion into new markets and product innovation. The company's ability to navigate regulatory hurdles and scale production will be crucial for future success. Investors should carefully consider the risks associated with OTC-listed companies and the evolving regulatory landscape surrounding medical marijuana.
Based on FMP financials and quantitative analysis
RBII Key Highlights
- P/E ratio of 0.21 suggests potential undervaluation compared to earnings.
- Profit margin of 6.4% indicates the company's ability to generate profit from revenue.
- Gross margin of 57.3% reflects efficient production and pricing strategies.
- Beta of 4.96 signifies high volatility relative to the market.
- Operates in the medical marijuana sector, offering exposure to a high-growth market.
Who Are RBII's Competitors?
RBII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RBII's Key Strengths?
- Specialization in topical and oral pharmaceutical products.
- Presence in the growing medical marijuana market.
- Established manufacturing capabilities.
- Potential for product innovation.
What Are RBII's Weaknesses?
- Limited market capitalization.
- High beta indicating significant volatility.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
What Could Drive RBII Stock Higher?
- Potential regulatory approvals for new pharmaceutical products.
- Expansion into new geographic markets.
- Development of new pharmaceutical formulations.
- Strategic partnerships and collaborations.
What Are the Key Risks for RBII?
- Negative return on equity (-4.4%) — the business is not currently generating profit on shareholder capital.
- Stringent pharmaceutical regulations impacting product development and sales.
- Competition from established pharmaceutical companies.
- Fluctuations in the medical marijuana market affecting revenue.
- Product liability claims related to pharmaceutical products.
- Risks associated with OTC trading, including liquidity and volatility.
What Are the Growth Opportunities for RBII?
- Expansion into new geographic markets represents a significant growth opportunity for Rising BioSciences. As the legal landscape for medical marijuana evolves, the company can target states and countries with favorable regulations. This expansion could involve establishing new distribution channels, partnerships, or even production facilities in strategic locations. The global medical cannabis market is projected to reach $55 billion by 2026, offering substantial revenue potential for companies that can successfully navigate regulatory hurdles and establish a strong market presence.
- Product innovation and development of new formulations can drive growth for Rising BioSciences. By investing in research and development, the company can create novel topical and oral pharmaceutical products that address unmet medical needs. This includes exploring new delivery methods, combinations of active ingredients, and targeted therapies. The pharmaceutical industry is characterized by continuous innovation, and companies that can bring innovative products to market are well-positioned for growth. The timeline for product development can vary, but successful products can generate significant revenue streams.
- Strategic partnerships and collaborations can enhance Rising BioSciences' market reach and product portfolio. By partnering with other pharmaceutical companies, research institutions, or distributors, the company can access new technologies, markets, and expertise. These partnerships can accelerate product development, expand distribution networks, and enhance brand recognition. Strategic alliances are common in the pharmaceutical industry, and they can provide a competitive advantage for companies seeking to grow and expand their operations. The timeline for establishing strategic partnerships can vary, but successful collaborations can yield long-term benefits.
- Focusing on niche markets within the medical pharmaceutical sector can provide a competitive advantage for Rising BioSciences. By targeting specific therapeutic areas or patient populations, the company can develop specialized products and services that meet unique needs. This includes exploring opportunities in areas such as pain management, dermatology, and mental health. Niche markets often offer higher margins and less competition than broader markets. The timeline for developing and marketing niche products can be shorter than for mainstream products, allowing for faster revenue generation.
- Leveraging digital marketing and e-commerce platforms can enhance Rising BioSciences' brand awareness and sales. By establishing a strong online presence, the company can reach a wider audience and promote its products directly to consumers. This includes developing a user-friendly website, engaging in social media marketing, and utilizing search engine optimization techniques. Digital marketing can be a cost-effective way to build brand awareness and drive sales. The timeline for implementing digital marketing strategies can vary, but consistent efforts can yield significant results over time.
What Opportunities Does RBII Have?
- Expansion into new geographic markets.
- Development of new pharmaceutical formulations.
- Strategic partnerships and collaborations.
- Focusing on niche markets within the medical pharmaceutical sector.
What Threats Does RBII Face?
- Stringent pharmaceutical regulations.
- Competition from established pharmaceutical companies.
- Fluctuations in the medical marijuana market.
- Potential for product liability claims.
What Are RBII's Competitive Advantages?
- Proprietary formulations for pharmaceutical products.
- Specialization in medical marijuana products.
- Established manufacturing capabilities.
- Compliance with pharmaceutical regulations.
What Does RBII Do?
Rising BioSciences, Inc. is a pharmaceutical company focused on the development and manufacturing of topical and oral pharmaceutical products. The company also produces medical marijuana products. Headquartered in Sheridan, Wyoming, Rising BioSciences operates within the healthcare sector, specifically targeting the medical pharmaceutical segment. The company's product line includes a range of pharmaceutical solutions, catering to various medical needs. Rising BioSciences aims to establish itself as a key player in the pharmaceutical market by focusing on product development and manufacturing. The company's strategic location in Sheridan, Wyoming, provides a base for its operations, allowing it to serve both regional and national markets. Rising BioSciences competes with other pharmaceutical companies, including those specializing in medical marijuana products, in a dynamic and regulated industry landscape. The company's success depends on its ability to innovate, comply with regulations, and effectively market its products. Rising BioSciences continues to explore opportunities for growth and expansion within the pharmaceutical sector.
What Products and Services Does RBII Offer?
- Develops topical pharmaceutical products.
- Manufactures oral pharmaceutical products.
- Produces medical marijuana products.
- Researches new pharmaceutical formulations.
- Markets and distributes pharmaceutical products.
- Complies with pharmaceutical regulations.
- Focuses on product innovation.
How Does RBII Make Money?
- Develops and manufactures pharmaceutical products.
- Sells products through distributors and potentially direct to consumers.
- Generates revenue through product sales.
What Industry Does RBII Operate In?
Rising BioSciences operates in the medical pharmaceutical industry, which is characterized by intense competition, stringent regulations, and continuous innovation. The market for medical marijuana products is expanding, driven by changing legal landscapes and increasing acceptance of cannabis-based treatments. Companies like ATTBF, AXMP, CEOS, HADV, and IMMB represent the competitive landscape. Rising BioSciences must navigate regulatory complexities and differentiate its products to gain market share. The industry is also influenced by factors such as research and development, clinical trials, and intellectual property protection.
Who Are RBII's Key Customers?
- Patients requiring topical and oral medications.
- Medical marijuana users.
- Pharmacies and medical dispensaries.
- Healthcare providers.
Company Profile
Rising BioSciences, Inc. operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Sheridan, US. The company is led by CEO Arthur Hall. RBII has traded publicly since 2017.
How Rising BioSciences, Inc. Is Valued
Rising BioSciences, Inc. carries a market capitalization of 5K, placing it in the micro-cap category.
ROE -4%Key Financial Metrics
Return on equity for Rising BioSciences, Inc. stands at -4.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 7.8%, showing how much profit it generates from its asset base. RBII trades at a trailing price-to-earnings ratio of 0.21, below the Healthcare sector average of ~23x. A current ratio of 0.12 means current liabilities exceed short-term assets, a liquidity point worth watching.
RBII Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Specialization in topical and oral pharmaceutical products.
- Presence in the growing medical marijuana market.
- Established manufacturing capabilities.
- Potential for product innovation.
Bear Case
- Limited market capitalization.
- High beta indicating significant volatility.
- Dependence on regulatory approvals.
- Competition from larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RBII Latest News
No recent news available for RBII.
RBII Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RBII.
Price Targets
Wall Street price target analysis for RBII.
RBII MoonshotScore
What does this score mean?
The MoonshotScore rates RBII's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Arthur Hall
CEO
Arthur Hall is the CEO of Rising BioSciences, Inc. His background includes experience in the pharmaceutical and healthcare industries. He has held various leadership positions, focusing on product development, manufacturing, and market expansion. Hall's expertise lies in navigating regulatory landscapes and driving innovation within the pharmaceutical sector. He is committed to growing Rising BioSciences and establishing it as a key player in the medical pharmaceutical market. His educational background includes studies in business administration and pharmaceutical sciences.
Track Record: Under Arthur Hall's leadership, Rising BioSciences has focused on developing and manufacturing topical and oral pharmaceutical products, including medical marijuana products. Hall has overseen the company's expansion into new markets and the development of innovative product formulations. He has also prioritized compliance with pharmaceutical regulations and the establishment of strategic partnerships. Hall's leadership has been instrumental in positioning Rising BioSciences for future growth and success.
RBII OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rising BioSciences may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and requires increased due diligence from investors compared to companies on more regulated exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower trading volume can lead to price volatility.
- Wider bid-ask spreads can increase transaction costs.
- Potential for delisting or suspension of trading.
- Higher risk of fraud or manipulation compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's compliance with regulations.
- Monitor trading volume and price volatility.
- Understand the risks associated with OTC investing.
- Consult with a financial advisor before investing.
- Development and manufacturing of pharmaceutical products.
- Presence in the medical marijuana market.
- CEO with experience in the pharmaceutical industry.
- Operation in the healthcare sector.
RBII Healthcare Stock FAQ
What does Rising BioSciences, Inc. do?
Rising BioSciences, Inc. is a pharmaceutical company that develops and manufactures topical and oral pharmaceutical products, including those containing medical marijuana. The company operates within the healthcare sector, focusing on the medical pharmaceutical segment. Rising BioSciences aims to provide pharmaceutical solutions to patients and healthcare providers through its product offerings. The company's business model involves product development, manufacturing, and distribution. Rising BioSciences competes with other pharmaceutical companies in a dynamic and regulated industry landscape.
What do analysts say about RBII stock?
As of March 18, 2026, there is no readily available analyst consensus on Rising BioSciences, Inc. (RBII) due to its OTC listing and limited coverage. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key valuation metrics include the P/E ratio of 0.21, profit margin of 6.4%, and gross margin of 57.3%. The company's high beta of 4.96 indicates significant volatility.
What are the main risks for RBII?
Rising BioSciences faces several risks, including stringent pharmaceutical regulations, competition from established pharmaceutical companies, fluctuations in the medical marijuana market, and potential product liability claims. As an OTC-listed company, RBII also faces risks associated with limited financial disclosure, lower trading volume, and wider bid-ask spreads. Investors should carefully consider these risks before investing in RBII. The company's high beta indicates significant volatility, which can amplify potential losses.
What are the key factors to evaluate for RBII?
Evaluate RBII on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does RBII data refresh on this page?
RBII prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RBII's recent stock price performance?
Rising BioSciences, Inc. (RBII) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialization in topical and oral pharmaceutical products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RBII overvalued or undervalued right now?
Valuing Rising BioSciences, Inc. (RBII) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RBII?
Before investing in Rising BioSciences, Inc. (RBII), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on Rising BioSciences, Inc. due to its OTC listing.
- AI analysis pending for RBII.